At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 300 target
Drug / intervention
S1 plus Docetaxel +1 moredrug
Likely dose
S1 plus Docetaxel 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study
In Brief
A Phase 2 clinical trial evaluating S1 plus Docetaxel and Capecitabine plus Docetaxel for Breast Cancer Recurrent. Targeting 300 participants across 1 site.
Detailed Summary
To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer Recurrent
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedOct 2016
Primary CompletionApr 2017
Study CompletionApr 2019
TodayJul 2026
First PostedOct 27, 2016
Enrollment StartApr 1, 2015
Primary CompletionApr 1, 2017
Study CompletionApr 1, 2019
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 9.7 years ago
Interventions
S1 plus Docetaxeldrug
S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
Capecitabine plus Docetaxeldrug
Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1